# Intravesical Cabazitaxel, Gemcitabine, and Cisplatin (CGC) in the Treatment Urothelial Carcinoma of the Bladder

> **NCT02202772** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Guarionex J. Decastro** · enrollment: 51 (actual)

## Conditions studied

- Urothelial Carcinoma of the Urinary Bladder

## Interventions

- **DRUG:** Cabazitaxel
- **DRUG:** Gemcitabine
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT02202772
- **Lead sponsor:** Guarionex J. Decastro
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2014-12-01
- **Primary completion:** 2026-04
- **Final completion:** 2028-04
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2025-02-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02202772

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02202772, "Intravesical Cabazitaxel, Gemcitabine, and Cisplatin (CGC) in the Treatment Urothelial Carcinoma of the Bladder". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02202772. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*